Cambridge, MA-based Faze Medicines announced its company launch on 10 December and plans to use its $81m series A financing to support preclinical research programs in amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Third Rock Ventures led the series A, which also included investments from Novartis Venture Fund, Eli Lilly and Company, AbbVie Ventures, Invus, Catalio Capital Management, Casdin Capital and Alexandria Venture Investments.
Founded by four academic scientists and experts in the field of biomolecular condensates and liquid-liquid phase transitions, Faze’s executive leadership...